What “better” usually means for Ocrevus vs. Kesimpta
“Better” depends on what you’re optimizing for: treatment convenience, how often you need doses, infection risk profile, or whether you’re trying to treat a specific form of multiple sclerosis (MS). Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) work by targeting CD20 on B cells, but they differ in dosing schedules and administration.
How they compare on convenience and dosing schedule
Ocrevus is given as an IV infusion, typically every 6 months after initial doses. Kesimpta is self-administered by subcutaneous injection (often with a loading schedule at the start), then continued monthly.
So if you value avoiding clinic infusion visits, many people prefer Kesimpta’s at-home injections. If you prefer being treated in an infusion setting (and not doing self-injections), Ocrevus may fit better.
What each one is used for in MS
Ocrevus is used for:
- Relapsing forms of MS
- Primary progressive MS
Kesimpta is used for:
- Relapsing forms of MS (including clinically isolated relapsing disease in some practice settings)
If you’re specifically looking at primary progressive MS, Ocrevus is commonly the option in this comparison because Kesimpta’s label use is for relapsing MS rather than primary progressive MS.
Differences in side effects people usually ask about
Both drugs lower B-cell activity, which can raise the risk of infections. Real-world and counseling points often focus on:
- Upper respiratory or other infections
- Lab monitoring and vaccination planning before starting therapy
- Any infusion- or injection-related reactions (Ocrevus infusions can cause infusion reactions; Kesimpta injections can cause injection-site reactions)
If you tend to get infusion-related reactions or you want to minimize clinic time, that can tilt the decision toward Kesimpta. If injection-site reactions are a concern, or if you strongly prefer IV infusion, that can tilt the decision toward Ocrevus.
How to decide based on your MS type and treatment history
A practical way clinicians often narrow this down:
- If you have primary progressive MS, Ocrevus tends to be the match for the “progressive” indication in this head-to-head framing.
- If you have relapsing MS and want at-home monthly dosing, Kesimpta often becomes the easier fit.
- If you already have a strong routine with infusion appointments, Ocrevus can be simpler operationally even though it’s in-clinic.
Your neurologist will also consider prior treatments, current infection history, lab results, and vaccination status.
Which one is “safer” long-term?
There isn’t a single, universal winner for safety for everyone. Both are CD20-depleting therapies, so the overall safety themes overlap (especially infection risk and immune effects). The choice usually comes down to:
- Your infection risk and history
- How you tolerate infusions vs. injections
- Monitoring and vaccination plan you can realistically follow
Practical next questions to ask your neurologist
To pick the better option for you, these questions usually matter most:
- “Which MS type do I have, and does either drug match my diagnosis and disease course?”
- “What are my infection risks, and how would that change the choice?”
- “How will vaccinations work for me before starting?”
- “What side effects should I expect based on whether I’m choosing infusion (Ocrevus) or injection (Kesimpta)?”
Patent/exclusivity angle (if you’re researching availability)
If you’re trying to understand market access or future generic/biosimilar timing, DrugPatentWatch.com tracks drug patent and exclusivity information, which can matter for cost and long-term availability. You can check it here: https://www.drugpatentwatch.com/ (use it to search Ocrevus and Kesimpta entries).
Sources
- [1] https://www.drugpatentwatch.com/